2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP01.06

PP01.06 - Sichao Wang

Pdf Summary

The study "NSAIDs Enhance the Efficacy of Mono-ICI in NSCLC: A Preclinical Validation Study" by Sichao Wang et al. investigates the effects of non-steroidal anti-inflammatory drugs (NSAIDs) on the efficacy of immune checkpoint inhibitors (ICIs) in treating non-small cell lung cancer (NSCLC). Previous clinical data suggested that NSAIDs provide significant survival benefits over acetaminophen (APAP) when used with ICIs in NSCLC patients. This preclinical study aimed to validate these findings using a C57BL/6 mouse model.<br /><br />The experiment involved six groups of mice: those receiving NSAIDs (celecoxib) combined with ICIs, APAP combined with ICIs, NSAIDs alone, APAP alone, ICIs alone, and a control group. Celecoxib was administered at 0.1 mg per mouse daily, and APAP at 30 mg/kg twice daily, from day 5 to 23. ICIs were given at 5 mg/kg on days 6, 9, 12, and 15. Tumor volume and overall survival (OS) were tracked, and immune response markers were assessed via ELISA in tissue and blood samples.<br /><br />Results showed that the NSAIDs and mono-ICI combination significantly reduced tumor volume and increased overall survival compared to the APAP/ICI and control groups. Enhanced immune activation markers, such as IFN-γ, CXCL3, and GZMB, and reduced IDO1 levels indicated an improved immune response in the NSAIDs/ICI group.<br /><br />The study concludes that NSAIDs enhance the efficacy of mono-ICI therapy by improving both immune response and survival outcomes in NSCLC. The researchers recommend further investigation into the mechanisms and potential clinical applications of these findings. The study was conducted by researchers from the University of Hong Kong and Shenzhen institutes.

Keywords

NSAIDs

immune checkpoint inhibitors

non-small cell lung cancer

preclinical study

celecoxib

C57BL/6 mouse model

tumor volume

immune response

overall survival

University of Hong Kong